Originalie
Batchelor TT et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weller, M. Rückschlag für Angiogenesehemmung. Info Onkol. 17, 20–21 (2014). https://doi.org/10.1007/s15004-014-0713-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-014-0713-5